Korro Bio (KRRO) Research & Development (2018 - 2026)
Korro Bio's (KRRO) quarterly Research & Development came in at $13.0 million in Q1 2026, down 34.39% YoY from $19.7 million in Q1 2025, and up 17.9% on a QoQ basis from $11.0 million in Q4 2025.
Korro Bio (KRRO) Research & Development (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Research & Development data on file, last reported at $13.0 million in Q1 2026.
- Quarterly Research & Development fell 34.39% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.8 million (down 15.78% YoY) and the FY2025 annual result came in at $65.6 million, up 3.05% from the prior year.
- Research & Development climbed to $13.0 million in Q1 2026, from $11.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $21.0 million in Q2 2025 to a low of -$39.3 million in Q4 2023.
- A 5-year average of $11.0 million and a median of $13.8 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development slumped 1245.92% — and 2024, when it surged 143.13%.
- Tracing KRRO's Research & Development over 5 years: stood at $3.4 million in 2022, then tumbled by 1245.92% to -$39.3 million in 2023, then surged by 143.13% to $17.0 million in 2024, then slumped by 35.24% to $11.0 million in 2025, then advanced by 17.9% to $13.0 million in 2026.
- The last three Research & Development figures came in at $13.0 million (Q1 2026), $11.0 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 13.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.59 Mn |
| Mar 31, 2026 | 12.95 Mn |
| Dec 31, 2025 | 10.99 Mn |
| Sep 30, 2025 | 13.82 Mn |
| Jun 30, 2025 | 21.03 Mn |
| Mar 31, 2025 | 19.74 Mn |
| Dec 31, 2024 | 16.96 Mn |
| Sep 30, 2024 | 15.96 Mn |
| Jun 30, 2024 | 17.14 Mn |
| Mar 31, 2024 | 13.57 Mn |
| Dec 31, 2023 | -39.33 Mn |
| Sep 30, 2023 | 14.01 Mn |
| Jun 30, 2023 | 13.13 Mn |
| Mar 31, 2023 | 14.69 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 11.72 Mn |
| Jun 30, 2022 | 13.27 Mn |
| Mar 31, 2022 | 13.78 Mn |
| Dec 31, 2021 | 12.75 Mn |
| Sep 30, 2021 | 15.66 Mn |